FDA panel backs Regeneron wet AMD drug, all eyes on pricing
This article was originally published in Scrip
Already rivaled by its own, much cheaper drug Avastin (bevacizumab), Roche unit Genentech could soon face another tough competitor for its vision-loss medication Lucentis (ranibizumab) if the US FDA takes the unanimous advice of its panel of outside experts to approve Regeneron's Eylea (aflibercept) to treat neovascular (wet) age-related macular degeneration (AMD).
You may also be interested in...
With new funding in hand, Moderna and its infectious disease venture Valera are going full-speed ahead with a Zika vaccine, taking an mRNA approach, which they said could be a more rapid strategy to try to stop the disease.
Allergan CEO Brent Saunders vows not to engage in price gouging and says his firm will limit cost increases to single-digit percentages, occurring only once per year. But it's unclear whether Saunders will stand as a lone wolf in the industry or if others will make similar pledges.
Hillary Clinton's plan to rein in high prices of older medicines, which includes creating a federal panel that has authority to impose fines, may grab headlines, but some analysts think it's unlikely to get very far in a divided Washington.